Free Trial

Traws Pharma (TRAW) Competitors

Traws Pharma logo
$1.58 -0.05 (-3.07%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.60 +0.01 (+0.95%)
As of 07/25/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRAW vs. KALA, MAAQ, KPTI, ITRM, HYPD, BDRX, SNYR, KZR, ESLA, and CLNN

Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include KALA BIO (KALA), Mana Capital Acquisition (MAAQ), Karyopharm Therapeutics (KPTI), Iterum Therapeutics (ITRM), Hyperion DeFi (HYPD), Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), Kezar Life Sciences (KZR), Estrella Immunopharma (ESLA), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry.

Traws Pharma vs. Its Competitors

Traws Pharma (NASDAQ:TRAW) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

KALA BIO has higher revenue and earnings than Traws Pharma. KALA BIO is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$230K38.19-$166.52M-$32.81-0.05
KALA BIO$3.89M13.41-$38.51M-$8.24-0.98

In the previous week, KALA BIO had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.89 beat KALA BIO's score of 0.17 indicating that Traws Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Traws Pharma Very Positive
KALA BIO Neutral

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 13.6% of Traws Pharma shares are held by insiders. Comparatively, 8.3% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Traws Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500.

KALA BIO has a consensus price target of $13.00, indicating a potential upside of 60.69%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Traws Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
KALA BIO
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

KALA BIO has a net margin of 0.00% compared to Traws Pharma's net margin of -15,245.81%. Traws Pharma's return on equity of 0.00% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws Pharma-15,245.81% N/A -193.21%
KALA BIO N/A -369.29%-64.99%

Summary

KALA BIO beats Traws Pharma on 10 of the 16 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRAW vs. The Competition

MetricTraws PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.07M$2.49B$5.69B$9.50B
Dividend YieldN/A1.65%4.58%4.01%
P/E Ratio-0.059.0528.1020.05
Price / Sales38.19612.51432.4490.07
Price / CashN/A165.2136.2258.56
Price / Book-0.185.168.665.87
Net Income-$166.52M$30.99M$3.25B$258.55M
7 Day Performance-1.25%7.74%4.23%3.74%
1 Month Performance10.49%16.27%10.52%11.75%
1 Year PerformanceN/A-1.88%34.41%18.03%

Traws Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRAW
Traws Pharma
0.9471 of 5 stars
$1.58
-3.1%
N/AN/A$9.07M$230K-0.0517Positive News
KALA
KALA BIO
3.9102 of 5 stars
$5.50
-3.5%
$13.00
+136.4%
+11.7%$35.49MN/A-0.6730
MAAQ
Mana Capital Acquisition
N/A$4.30
-6.9%
N/A+847.8%$34.94MN/A0.001Gap Up
KPTI
Karyopharm Therapeutics
3.8333 of 5 stars
$3.89
-3.2%
$37.40
+861.4%
-69.8%$33.61M$145.24M-0.29380
ITRM
Iterum Therapeutics
2.0519 of 5 stars
$0.83
-4.7%
$9.00
+984.3%
-35.8%$33.20MN/A-0.8410Positive News
HYPD
Hyperion DeFi
1.1236 of 5 stars
$11.52
-1.0%
$2.00
-82.6%
-93.3%$33.18M$60K-0.2040Positive News
Analyst Downgrade
Gap Up
BDRX
Biodexa Pharmaceuticals
0.2928 of 5 stars
$0.90
+6.0%
N/AN/A$32.93M$470K0.0020Positive News
SNYR
Synergy CHC
4.0745 of 5 stars
$3.56
+1.7%
$10.00
+180.9%
N/A$32.73M$33.59M0.0040Gap Down
KZR
Kezar Life Sciences
4.1212 of 5 stars
$4.45
+3.5%
$39.50
+787.6%
-34.5%$32.51MN/A-0.4160
ESLA
Estrella Immunopharma
3.2141 of 5 stars
$0.87
+4.0%
$16.00
+1,730.7%
-47.9%$31.61MN/A-3.36N/ANews Coverage
Gap Down
CLNN
Clene
3.4621 of 5 stars
$3.81
-1.6%
$40.00
+949.9%
-18.2%$31.51M$340K-0.94100

Related Companies and Tools


This page (NASDAQ:TRAW) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners